Efficacy of *Mycoplasma hyopneumoniae* vaccination before and at weaning against experimental challenge infection in pigs

Ioannis Arsenakis¹*, Luca Panzavolta¹, Annelies Michiels¹, Rubén Del Pozo Sacristán¹, Filip Boyen², Freddy Haesebrouck² and Dominiek Maes¹

**Abstract**

**Background:** Commercial bacterins are widely used at weaning to control *Mycoplasma hyopneumoniae* infections in pigs. However, it is not known whether the efficacy of vaccinating against *M. hyopneumoniae* can be influenced by the weaning process when vaccination is applied at the day of weaning. The present study assessed the efficacy of a single *M. hyopneumoniae* vaccination (Ingelvac MycoFLEX*) three days before weaning (V1) or at weaning (V2) against experimental challenge infection. Four weeks after vaccination, groups V1 and V2 (*n* = 20 pigs each) and a non-vaccinated, positive control group (PCG) (*n* = 20) were endotracheally inoculated with a virulent *M. hyopneumoniae* field strain. Five pigs were used as a negative control group. All pigs were euthanized 5 weeks after challenge. The main parameters investigated included macroscopic and histopathological lung lesions at necropsy, immunofluorescence (IF) staining and quantitative real-time PCR (qPCR) on broncho-alveolar lavage (BAL) fluid for quantifying *M. hyopneumoniae*.

**Results:** The average macroscopic lung lesion scores in groups V1, V2 and PCG were 0.54, 0.88 and 1.04, respectively (*P* > 0.05). The average lymphohistiocytic infiltration scores in groups V1, V2 and PCG were 2.95, 3.16 and 3.61, respectively (*P* < 0.05). The average IF scores were: V1 = 1.13, V2 = 1.19 and PCG = 1.25 (*P* > 0.05), the qPCR values were: V1 = 10^{2.94}, V2 = 10^{2.76} and PCG = 10^{3.23} (*P* > 0.05). All pigs of the negative control group remained negative throughout the study.

**Conclusions:** Both vaccinated groups had lower numbers of macroscopic and histopathological lung lesions, and lower numbers of *M. hyopneumoniae* organisms in the BAL fluid compared to the PCG. However, no firm conclusions could be made on whether weaning negatively influences the efficacy of *M. hyopneumoniae* vaccination, since significant differences between the treatment groups were only obtained for the histopathological lung lesions. This could be attributed to the fact that milder macroscopic lung lesions were produced in the inoculated pigs, when compared to previous trials conducted by the same group. Further research under field conditions is warranted to assess possible differences between the two vaccination strategies.

**Keywords:** Weaning, *Mycoplasma hyopneumoniae*, Vaccination, Efficacy, Strain

*Correspondence: Ioannis.Arsenakis@UGent.be*

¹Porcine Health Management Unit, Department of Reproduction, Obstetrics & Herd Health, Faculty of Veterinary Medicine, Ghent University, Salisburylaan 133, Merelbeke 9820, Belgium

© 2016 Arsenakis et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Mycoplasma hyopneumoniae is the etiological agent of enzootic pneumonia (EP), a chronic respiratory disease affecting mainly grow-finishing pigs [1, 2]. M. hyopneumoniae infections have been detected in almost all countries with intensive production systems and are responsible for major economic losses in the pig industry [1, 3]. These economic losses are due to pig growth retardation, higher feed conversion ratios, increased antimicrobial use and increased susceptibility to other respiratory pathogens such as Pasteurella multocida, Actinobacillus pleuropneumoniae, Trueperella pyogenes and Streptococcus suis [4]. M. hyopneumoniae is also an important pathogen involved in the porcine respiratory disease complex (PRDC) [5, 6].

Control of M. hyopneumoniae infections can be achieved in a number of ways, such as optimizing management and housing conditions, antimicrobial medication and vaccination. In many countries, more than 70 % of pig herds are vaccinated against M. hyopneumoniae in an effort to control the disease [7]. Vaccination with commercial bacterins has been extensively proven to reduce performance losses, the severity of clinical signs and lung lesions [8–12]. Different vaccination schemes can be implemented, depending on the type of herd, the production system, the infection pattern and the preference of the farmer.

Currently, both double and single vaccination strategies are widely practiced. Single vaccination is often administered either at 1 week of age or at weaning. Vaccination is often done at weaning because the piglets are handled then anyway, so vaccination can easily be included in routine farm management practices [12, 13]. On the other hand, weaning is one of the most stressful events in the pig’s life [14, 15]. The piglets are then experiencing the abrupt separation from the sow, they are being handled, they are being moved to other facilities, they are usually being mixed with other pigs, and they are receiving a different type of feed [14, 15]. Stress may interfere with an optimal response to vaccination, and therefore it is generally recommended not to vaccinate animals that are severely stressed [16].

Consequently, one important question that remains to be answered, and whose answer could contribute to the optimization of existing vaccination schemes, is whether the efficacy of vaccinating against M. hyopneumoniae can be influenced by the weaning process when vaccination is applied at the day of weaning. The objective of this trial was to investigate the efficacy of a one-shot vaccination applied either at weaning or three days before weaning in pigs experimentally infected with a virulent M. hyopneumoniae field strain.

Results
Clinical and performance parameters
In total, two pigs died during the trial, after receiving the endotracheal challenge infection (one in the V2 group and one in the PCG group). These pigs were not included in the analysis. In groups V1, V2 and PCG, coughing started approximately six days after challenge and continued to increase towards the end of the trial. In groups V1 and V2, coughing peaked between 66 and 70 days of age, whereas in the PCG, the peak was noticed at 80 days of age. The respiratory disease score (RDS) values for the period before challenge and the period after challenge, as well as for the overall period, are shown in Table 1. There were no significant differences between the groups (P > 0.05).

The average daily weight gain (ADG) results of groups V1, V2 and PCG during the period before challenge and during the period after challenge, as well as during the overall period, are presented in Table 2. There were no significant differences (P > 0.05) between the groups.

Macroscopic and histopathological lung lesions, and IF testing for M. hyopneumoniae
Only numerical differences in macroscopic lung lesions (P > 0.05) were found between groups V1, V2 and PCG (Table 3). The lowest average macroscopic lung lesion score was given to group V1 (0.54). The average lung lesion scores of the pigs in groups V2 and PCG were 0.88 and 1.04, respectively. There were no macroscopic lung lesions in the negative control group.

Statistically significant differences (P < 0.05) in histopathological lung lesions were present between groups V1, V2 and PCG (Table 3). The average lymphohistocytic infiltration score was lower in group V1 (2.95) when compared with groups V2 (3.16) and PCG (3.61). The V1 group had the highest average percentage of air in the lung tissue (44.28), followed by group V2 (37.47) and PCG (31.46).

The results from the IF testing that was used to semi-quantitatively assess the load of M. hyopneumoniae organisms in the lung tissue, namely 1.13 (group V1),
Table 2: ADG (± standard deviation SD) of each treatment group during the three different periods

| Age range (days) | Treatment | ADG (±SD) (g/pig/day) | P value |
|------------------|-----------|------------------------|---------|
| 20–48            | V1 (n = 20) | 293 ± 41               | 0.491   |
|                  | V2 (n = 19) | 299 ± 42               |         |
|                  | PCG (n = 19) | 303 ± 55               |         |
| 48–83            | V1 (n = 20) | 701 ± 116              | 0.442   |
|                  | V2 (n = 19) | 681 ± 129              |         |
|                  | PCG (n = 19) | 718 ± 140              |         |
| 20–83            | V1 (n = 20) | 519 ± 56               | 0.461   |
|                  | V2 (n = 19) | 511 ± 66               |         |
|                  | PCG (n = 19) | 533 ± 71               |         |

Treatment groups: V1 (vaccinated before weaning, at 18 days of age, challenge infected), V2 (vaccinated on the day of weaning, at 21 days of age, challenge infected) and PCG (non-vaccinated, challenge infected). Overall and pairwise comparisons did not reveal any significant differences between the groups for the three different periods. D48: experimental infection, D83: euthanasia.

1.19 (group V2) and 1.25 (PCG), were not significantly different (P > 0.05) between groups (Table 3). All pigs of the negative control group were negative for IF staining.

qPCR assay and bacteriological examination

The number of M. hyopneumoniae organisms quantified by qPCR in the BAL fluid was not significantly different (P > 0.05) between groups V1, V2 and PCG (Table 3). Lower numbers of organisms were detected in groups V1 and V2 (10^{2.94} and 10^{2.76} copies/mL, respectively) compared to group PCG (10^{3.23} copies/mL). No M. hyopneumoniae DNA was detected in pigs of the negative control group.

Several bacteria were isolated from BAL fluid. In groups V1 and V2, Bordetella bronchiseptica (V1: 3/20 pigs; V2: 1/20 pigs) and polybacterial cultures (V1: 4/20 pigs; V2: 2/20 pigs) were obtained. In the PCG, Haemophilus parasuis (1/20 pigs), S. suis (1/20 pigs) and polybacterial cultures (1/20 pigs) were obtained. The bacteriological culture remained negative for all pigs in the negative control group.

Serology

The serological results for M. hyopneumoniae at 21, 48 and 83 days of age are presented in Table 4. At 21 days of age, all the piglets were serologically negative for M. hyopneumoniae. At 48 days of age, 40 % of the pigs in each of the vaccinated groups V1 and V2 had seroconverted. None of the pigs in the PCG had seroconverted to M. hyopneumoniae at that time. At 83 days of age, all the pigs in groups V1 and V2 were seropositive, while 95 % of the pigs in the PCG had seroconverted. All pigs in the negative control group were serologically negative at all time-points.

Discussion

The present experimental trial investigated whether the efficacy of one-shot vaccination is influenced by the weaning process. Differences between V1 (vaccination three days before weaning), V2 (vaccination at weaning) and the PCG (no vaccination) were small and mostly statistically not significant, except for the microscopic lung lesions, which were lower in V1.

Apart from the transport related to the weaning process, the piglets in the present study were also transported to the experimental facilities, a trip that lasted anywhere from one-half to two hours. In fact, age- and site-segregated pork production is a complex process that involves movement of the piglets from the farrowing house to the nursery facilities, which are situated in different locations [17]. It can be expected, though, that the stress imposed on the piglets in our study may have been greater than when the piglets remain on the same site and are not transported (e.g. in single site farrow-to-finish pig herds) [18].

Vaccination at the moment of weaning, when the piglets are being handled anyway, is a common practice, as it can be implemented easily in the daily management of a pig herd. The pigs of V1 were vaccinated three days before weaning. This vaccination strategy is also commonly practiced by some pig producers in order to avoid any possible negative effects of the weaning process, and/or to avoid too much handling or interventions on the same day [19]. A difference of three days between

Table 3: Average (± standard deviation SD) values of macroscopic and histopathological lung lesion scores, IF scores, and qPCR.

| Parameter                          | V1 (n = 20) | V2 (n = 19) | PCG (n = 19) | P value |
|------------------------------------|-------------|-------------|-------------|---------|
| Macroscopic lung lesions           | 0.54 ± 0.67^A | 0.88 ± 1.45^A | 1.04 ± 2.45^A | 0.777   |
| Lymphohistiocytic infiltration     | 2.95 ± 0.50^A | 3.16 ± 0.58^B | 3.61 ± 0.59^C | 0.002   |
| Percentage of air in lung tissue   | 44.28 ± 14.68^A | 37.47 ± 17.76^B | 31.46 ± 14.51^C | 0.000   |
| IF                                 | 1.13 ± 0.54^A | 1.19 ± 0.79^A | 1.25 ± 0.70^A | 0.896   |
| qPCR on BAL fluid                  | 10^{2.94} ± 10^{1.24A} | 10^{2.76} ± 10^{1.48A} | 10^{1.23} ± 10^{1.33A} | 0.616   |

Treatment groups: V1 vaccinated before weaning, at 18 days of age, challenge infected, V2 vaccinated at weaning, at 21 days of age, challenge infected, and PCG positive control group i.e. non-vaccinated, challenge infected.

Values with different superscript (A-C) in capital letter within a row are significantly different (P ≤ 0.05).

* Macroscopic lung lesion scoring based on Hannan et al. [30].

Lymphohistiocytic infiltration score based on Morris et al. [31].

Percentage of air in lung tissue measured by means of automatic image analysis system (Optimas* 6.5, Media Cybernetics, Silver Spring, USA).

IF scoring based on Kobisch et al. [32].

Values from qPCR on BAL fluid expressed as copies of M. hyopneumoniae/mL.
the two vaccination groups most probably allowed sufficient time for the development of the first and most critical steps of the immune response prior to the stress of weaning [20]. At the same time, too great a difference in age at vaccination was avoided between the piglets in the V1 and V2 groups. In this sense, the two vaccination schemes are relevant for the situation in many pig herds.

The experimental infection model used for *M. hyopneumoniae* was similar to that used in previous trials [21–24]. Challenge infection proved to be successful since the vast majority of the infected pigs had positive qPCR values, exhibited the presence of *Mycoplasma*-like macroscopic lung lesions at necropsy and were positive for IF staining. However, the macroscopic lung lesions observed in the present trial were milder compared to trials that had been previously conducted using the same inoculation dose of *M. hyopneumoniae* F7.2C field strain, experimental facilities and way of allocation [23–25]. The precise reasons for this difference are not known. Based on the macroscopic lung lesion scores, serology, qPCR testing and IF staining, all the pigs in the negative control group were negative for *M. hyopneumoniae* throughout the trial, thus confirming that the study piglets were free of *M. hyopneumoniae*.

The RDS values in the PCG were similar to those mentioned in other experimental trials [22, 24]. Compared with the vaccinated groups V1 and V2, the only differences found in the PCG were numerical. There were no significant differences in ADG between the groups. This is mainly due to the high standard deviations observed and the limited numbers of pigs. ADG was measured, but it was not considered an important parameter for this experimental study. In vaccination trials under field conditions however, in which many more animals can be included, ADG is an important parameter.

Group V1 had the lowest numbers of macroscopic and histopathological lung lesions, and the lowest IF scores when compared to groups V2 and PCG. Nevertheless, significant differences between groups V1, V2 and PCG were only obtained for the histopathological lung lesions. This was confirmed by the results of the percentage of air parameter in the lung tissue measured by means of an automatic image analysis system. The statistically significant differences between groups V1, V2 and PCG proved that *M. hyopneumoniae* vaccination is effective in reducing lymphohistiocytic infiltration and increasing the percentage of air in the lung. This reduction of the lymphohistiocytic infiltration scores in the vaccinated groups is in accordance with previous experimental trials [22, 24]. The less severe histopathological lesions may be due to a modulation of the immune response in vaccinated animals. It has been shown that vaccination with a bacterin against *M. hyopneumoniae* reduces the infiltration of macrophages in the lung tissue [26].

Although lower qPCR values were recorded in the vaccinated groups when compared to the PCG, it was not possible to conclude whether vaccination was associated with the reduced bacterial load in the lungs, since the differences between the groups were only numerical. However, the detection of *M. hyopneumoniae* in the BAL fluid of groups V1 and V2 confirms that vaccination alone is not able to prevent colonization of the pig’s respiratory tract [4, 22, 24].

The pigs of groups V1, V2 and PCG were seronegative for *M. hyopneumoniae* on the day of transportation to the experimental facilities. At the time of inoculation, 40 % of the pigs in each of the vaccinated groups V1 and V2 had seroconverted. This is in agreement with other studies which have reported that vaccination with commercial bacterins induces seroconversion rates ranging from 30 to 100 % [4, 27]. At necropsy, all the pigs in groups V1 and V2 were seropositive, while the percentage of pigs that had seroconverted in group PCG was 95 %.

Overall, no firm conclusions could be made as to whether group V1 performed better than groups V2 and PCG, since only the microscopic lung lesions were significantly lower in the pigs in group V1. Further research under field conditions is necessary to elucidate the possible effect of weaning on the efficacy of one-shot *M. hyopneumoniae* vaccination. Field trials make it possible to include more animals and to study the entire course of *M. hyopneumoniae* infections up to the time of slaughter.

**Conclusions**

In conclusion, the differences between the vaccinated groups V1 and V2 were small and mostly statistically not significant. Thus, no firm conclusions could be made as to whether the process of weaning had a negative impact on the efficacy of vaccinating against *M. hyopneumoniae*. A future field trial could possibly provide further insight on the same topic.

---

**Table 4** Percentage of seropositive pigs in the different groups at different time-points during the trial

| Days of age | V1 (n = 20) | V2 (n = 19) | PCG (n = 19) |
|------------|-------------|-------------|-------------|
| 21<sup>a</sup> | 0           | 0           | 0           |
| 48<sup>b</sup> | 40          | 40          | 0           |
| 83<sup>c</sup> | 100         | 100         | 95          |

Treatment groups: V1 (vaccinated before weaning, at 18 days of age, challenge infected), V2 (vaccinated on the day of weaning, at 21 days of age, challenge infected), PCG (non-vaccinated, challenge infected) and NCG (non-vaccinated, non-challenge infected)

* Day of weaning and transport to the animal facilities of the Faculty of Veterinary Medicine, Ghent University

<sup>a</sup> Inoculation time

<sup>b</sup> Necropsy
Methods

Animals

Sixty-five cross-bred piglets (Topigs 20 sows and Pietrain boars) were purchased from a herd that was free of *M. hyopneumoniae* and PRRSV. Sows and fattening pigs of different age groups in the herd had been repeatedly monitored clinically and serologically, and then by means of macroscopic pneumonia lung lesions at slaughter, and no evidence for the presence of *M. hyopneumoniae* or PRRSV in the herd was found at 3 weeks of age (day seven), the piglets were weaned and transported for one-half to two hours to the animal facilities of the Faculty of Veterinary Medicine, Ghent University, Belgium. From this point onwards, all the pigs received *ad libitum* a commercial, antibiotic-free feed.

Experimental design and *M. hyopneumoniae* inoculation

At 14 days of age, prior to purchase, piglets from 20 different litters were individually ear-tagged and randomly allocated to four different groups. The three main treatment groups were: V1 (vaccinated before weaning, at 18 days of age and while still on the farm; *n* = 20), V2 (vaccinated during weaning, at 21 days of age and before being transported to the experimental facilities; *n* = 20) and a non-vaccinated positive control group (PCG; *n* = 20). Five pigs were used as a negative control group, to verify that they remained free of *M. hyopneumoniae*. They were not vaccinated. The pigs in groups V1 and V2 received a single-shot intramuscular (i.m.) injection (1 mL) of a commercial *M. hyopneumoniae* bacterin vaccine (Ingelvac MycoFLEX®, Boehringer Ingelheim Vetmedica). The pigs in PCG were left untreated and were not injected with a placebo or a non-vaccinated positive control group (PCG; *n* = 20). Five pigs were used as a negative control group, to verify that they remained free of *M. hyopneumoniae*. They were not vaccinated. The pigs in groups V1 and V2 received a single-shot intramuscular (i.m.) injection (1 mL) of a commercial *M. hyopneumoniae* bacterin vaccine (Ingelvac MycoFLEX®, Boehringer Ingelheim Vetmedica). The pigs in PCG were left untreated and were not injected with a placebo to simulate field conditions. Upon arrival at the Faculty of Veterinary Medicine, each group was housed in a different experimental room equipped with a high efficiency particulate air filter to avoid possible transmission of the pathogen between groups.

At 48 days of age, the two vaccinated groups, V1 and V2, as well as the PCG were challenge infected endotracheally with a 7 mL inoculum containing 10⁷ color changing units per mL of the virulent *M. hyopneumoniae* F7.2C field strain as described previously [28]. The pigs in the negative control group were inoculated with 7 mL of sterile culture medium. For the inoculations, the pigs were anaesthetized by administering a mixture of Xyl-M® 2 % and Zoletil 100® i.m. at a dose rate of 0.3 mL/kg bodyweight.

All animals were euthanized and necropsied at 83 days of age. Deep anesthesia was induced by administering i.m. 0.3 mL/kg of a mixture of Xyl-M® 2 % and Zoletil 100®, followed by exsanguination. The study was approved by the ethical committee for animal experiments of the Faculty of Veterinary Medicine, Ghent University (EC2013/35).

Parameters of comparison

Clinical and performance parameters

Each treatment group was examined daily for a minimum of 15 min for the presence of clinical signs throughout the entire trial period. Coughing severity was evaluated in a blinded manner by means of an RDS on a scale from 0 to 6 [29]. According to that scale: 0 (no coughing), 1 (mild coughing after being encouraged to move), 2 (mild coughing while at rest), 3 (moderate coughing after being encouraged to move), 4 (moderate coughing while at rest), 5 (severe coughing after being encouraged to move), and 6 (severe coughing while at rest). The daily RDS values were averaged for the three following periods: from day 29 until day 47, from day 48 (day of inoculation) until day 83 (day of necropsy), and from day 29 until day 83.

Individual bodyweights were measured at 20, 48 and 83 days of age to determine the ADG of each treatment group during the three following periods: from day 20 until day 48, from day 48 until day 83 and from day 20 until day 83.

Macroscopic and histopathological lung lesions, and IF testing for *M. hyopneumoniae*

After necropsy, *Mycoplasma*-like macroscopic lung lesions were quantified in a blinded manner using a lung lesion score diagram [30]. Theoretically, the total lung lesion scores could range between 0 (absence of lesions) and 35 (entire lung affected).

Two lung tissue samples per lobe (apical, cardiac and diaphragmatic) were collected from the right lung of each pig for histopathology and IF testing. Samples were collected from the edges of the lung lesions, if present [24].

For histopathology, the tissue was fixed in 10 % neutral buffered formalin and routinely processed and embedded in paraffin. One slide was made per lobe sample. Using light microscopy, the severity of peribronchiolar and perivascular lymphohistiocytic infiltration and nodule formation consistent with *M. hyopneumoniae* lesions were scored on a scale from 1 to 5 [31]. Scores 1 and 2 were classified as lesions not related to *Mycoplasma* infections. Scores 3, 4 and 5 were considered to be associated with *Mycoplasma* infections (mild, moderate and severe lesions characteristic of broncho-interstitial (cuffing) pneumonia, surrounding the bronchioles but extending to the interstitium, with lymphofollicular infiltration and mixed inflammatory cell exudates). After three lobes per pig were investigated, the average score per treatment group was calculated.

The percentage of lung area occupied by air (percentage air) was examined by means of an automatic image
analysis system (Optimas° 6.5, Media Cybernetics, Silver Spring, USA). This percentage is inversely proportional to the severity of peribronchiolar and perivascular lymphohistiocytic infiltration in the lung tissue and the amount of intrabronchiolar – intrabronchial exudate. An average percentage per treatment group was calculated [28].

A direct IF assay was performed to assess the presence of *M. hyopneumoniae* in the lungs. The scores given could range from 0 to 3: 0 (no IF), 1 (limited IF), 2 (moderate IF), and 3 (intense IF) [32].

**qPCR and bacteriological examination**

During necropsy, BAL fluid was collected from the left part of the lungs before the tissue samples for histopathology and IF were taken [21]. The recovered fluid was divided into two aliquots, immediately cooled to 4 °C, and then stored at −70 °C until analysis. The first aliquot was used to quantify *M. hyopneumoniae* organisms by qPCR [33]. DNA was extracted (Qiagen, Blood and tissue kit, Belgium) and qPCR was performed using the CFX96 real-time PCR detection system (Bio-Rad). The analysis was done in a double-replicate single setting. To convert the threshold values to the number of organisms, a tenfold dilution series of *M. hyopneumoniae* DNA was used. Values below the last dilution were considered as negative.

The second aliquot of BAL fluid was used for routine bacteriological culture to detect the presence of *Actinobacillus* and *Haemophilus* spp., and other pathogens which may affect the respiratory tract, such as *S. suis*, *B. bronchiseptica*, *P. multocida* and *T. pyogenes* [24].

**Serology for *M. hyopneumoniae***

Blood samples were collected from all pigs at 21, 48 and 83 days of age to measure antibodies against *M. hyopneumoniae*, using a blocking ELISA (IDEIA, *M. hyopneumoniae* EIA kit, Oxoid, UK) [12]. Sera with optical density (OD) values < 50 % of the ODbuffer-control were considered positive, while sera with OD values ≥ 50 % of the ODbuffer-control were considered negative.

**Statistical analysis**

The statistical analysis was performed on groups V1, V2 and PCG. Pigs of the negative control group (n = 5) were not included, as they were only employed to ensure that the animals remained free of *M. hyopneumoniae* throughout the experiment. The RDS data were analyzed using repeated measures analysis of variance (ANOVA). Levene’s test was used to assess the homogeneity of the variances between the different groups. The ADG, macroscopic and histopathological lung lesions, percentage of air in the lungs, IF testing and qPCR were analyzed with a non-parametric Kruskal-Wallis ANOVA. These five continuous variables did not fulfill the criteria for homogeneity of variances. Statistical results were considered significant when the P-values were ≤ 0.05 (two-sided test). The statistical package SPSS 21.0 for Windows (SPSS Inc., IL, USA) was used to analyze the data.

**Competing interests**

The authors declare that they have no competing interests.

**Authors’ contributions**

JA performed the lab work and the statistical analyses, interpreted the data and wrote all the drafts of the manuscript. LP was involved in the lab analyses and the trial. AM and RDPS were involved in the performance of the trial and the review of the final manuscript. FB, FH and DM contributed to the development of the protocol, the planning of the study, the review of the final manuscript and the approval for publication. All the authors read and approved the final manuscript.

**Acknowledgements**

The study was financially supported by Boehringer-Ingelheim Vetmedica GmbH, Ingelheim am Rhein, Germany. The authors are grateful to Ria Spiessens and Els De Fré for their technical assistance in numerous arrangements of the trial.

**Author details**

1. Porcine Health Management Unit, Department of Reproduction, Obstetrics & Herd Health, Faculty of Veterinary Medicine, Ghent University, Salisburylaan 133, Merelbeke 9820, Belgium.
2. Department of Pathology, Bacteriology and Avian Diseases, Faculty of Veterinary Medicine, Ghent University, Salisburylaan 133, Merelbeke 9820, Belgium.

Received: 23 January 2015 Accepted: 17 March 2016

**References**

1. Vicca J, Maes D, Thermote L, Peeters J, Hasebebruck F, Kruif AD. Patterns of *Mycoplasma hyopneumoniae* infections in Belgian farrow-to-finish pig herds with diverging disease-course. J Vet Med. 2002;49:49–53.
2. Sibila M, Bernal R, Torrents D, Rera P, Llopart D, Calsamiglia M, et al. Effect of sow vaccination against *Mycoplasma hyopneumoniae* on sow and piglet colonization and seroconversion, and pig lung lesions at slaughter. Vet Microbiol. 2008;127:165–70.
3. Thacker EL. Mycoplasmal disease. In: Straw BE, Zimmermann JJ, D’Allaire S, Taylor DJ, editors. Diseases of swine. Ames: Wiley-Blackwell Publishing; 2006. p. 701–17.
4. Maes D, Segales J, Meyns T, Sibila M, Pieters M, Hasebebruck F. Control of *Mycoplasma hyopneumoniae* infections in pigs. Vet Microbiol. 2008;126:297–309.
5. Fablet C, Marois C, Kunzt-Simon G, Rose N, Dorenlar V, Eono F, et al. Longitudinal study of respiratory infection patterns of breeding sows in five farrow-to-finish herds. Vet Microbiol. 2011;147:329–39.
6. Del Pozo Sacristán R, Rodríguez AL, Sierens A, Vanckx K, Boyen F, Dereu A, et al. Efficacy of on-feed medication with chlorotetracycline in a farrow-to-finish herd against a clinical outbreak of respiratory disease in fattening pigs. Vet Rec. 2012;171:22–9.
7. Villareal I, Vanckx K, Duchateau L, Passmans F, Hasebebruck F, Jensen JC, et al. Early *Mycoplasma hyopneumoniae* infections in European suckling pigs in herds with respiratory problems: detection rate and risk factors. Vet Med-Czech. 2010;55:318–24.
8. Maes D, Deluyker H, Verdonck M, Castryck F, Miny C, Lein A, et al. Effect of vaccination against *Mycoplasma hyopneumoniae* in pig herds with a continuous production system. J Vet Med. 1998;45:495–505.
9. Maes D, Deluyker H, Verdonck M, Castryck F, Miny C, Vrijens B, et al. Effect of vaccination against *Mycoplasma hyopneumoniae* in pig herds with an all-in/all-out production system. Vaccine. 1999;17:1024–34.
10. Jensen CS, Erdsboll AK, Nielsen JP. A meta-analysis comparing the effect of vaccines against *Mycoplasma hyopneumoniae* on daily weight gain in pigs. Prev Vet Med. 2002;54:265–78.
11. Wilson S, Van Brussel L, Saunders G, Taylor L, Zimmermann L, Heinritz K, et al. Vaccination of piglets at 1 week of age with an inactivated Mycoplasma hyopneumoniae vaccine reduces lung lesions and improves average daily gain in body weight. Vaccine. 2012;30:7625–32.

12. Del Pozo Sacristán R, Siérens A, Marchioro SB, Vangroenweghe F, Jourquin J, Labarque G, et al. Efficacy of early Mycoplasma hyopneumoniae vaccination against mixed respiratory disease in older fattening pigs. Vet Rec. 2013;174:197–202.

13. Alacron P, Wieland B, Mateus ALP, Dewberry C. Pig farmers’ perceptions, attitudes, influences and management of information in the decision-making process for disease control. Prev Vet Med. 2013;116:223–42.

14. Piél S, Laléis JP, Blazy F, Laffitte J, Seve B, Oswald IP. Weaning is associated with an upregulation of expression of inflammatory cytokines in the intestine of piglets. J Nutr. 2004;134:641–7.

15. Campbell JM, Crenshaw JD, Polo J. The biological stress of early weaned piglets. J Anim Sci Biotechnol. 2013;4:19.

16. Chase CCL, Lunney JK. Immune system. In: Zimmerman JJ, Kamiker L, Ramirez A, Schwartz K, Stevenson G, editors. Diseases of swine. Ames, IA: Wiley-Blackwell Publishing; 2012. p. 227–50.

17. Whiting TL, Brandt S. Minimum space allowance for transportation of swine by road. Can Vet J. 2002;43:207–12.

18. Lambooi E. Transport of pigs. In: Grandin T, editor. Livestock handling and transport. Wallingford, UK: CAB International; 2012. p. 228–45.

19. Gillespie JR, Flanders FKB. Modern livestock and poultry production. 8th ed. New York: Delmar; 2010.

20. Kick AR, Tompkins MB, Hammer JM, Routh PA, Almond GW. Evaluation of peripheral lymphocytes after weaning and vaccination for Mycoplasma hyopneumoniae. Res Vet Sci. 2011;91:68–72.

21. Villareal I, Maes D, Meyns T, Gebruers F, Calus D, Pasmans F, et al. Infection with a low virulent Mycoplasma hyopneumoniae isolate does not protect piglets against subsequent infection with a highly virulent M. hyopneumoniae isolate. Vaccine. 2009;27:1875–79.

22. Villareal I, Maes D, Vranckx K, Calus D, Pasmans F, Haesebrouck F. Effect of vaccination of pigs against experimental infection with high and low virulence Mycoplasma hyopneumoniae strains. Vaccine. 2011;29:1731–35.

23. Del Pozo Sacristán R, Thiry J, Vranckx K, Rodríguez AL, Chiers K, Haesebrouck F, et al. Efficacy of florfenicol injection in the treatment of Mycoplasma hyopneumoniae induced respiratory disease in pigs. Vet J. 2012;194:420–22.

24. Villareal I, Vranckx K, Calus D, Pasmans F, Haesebrouck F, Maes D. Effect of challenge of pigs previously immunized with inactivated vaccines containing homologous and heterologous Mycoplasma hyopneumoniae strains. BMC Vet Res. 2012;8:2.

25. Meyns T, Dewulf J, De Kruijff A, Calus D, Haesebrouck F, Maes D. Comparison of transmission of Mycoplasma hyopneumoniae in vaccinated and non-vaccinated populations. Vaccine. 2006;24:7081–86.

26. Vranckx K, Maes D, Marchioro SB, Villareal I, Chiers K, Pasmans F, et al. Vaccination reduces macrophage infiltration in bronchus-associated lymphoid tissue in pigs infected with a highly-virulent Mycoplasma hyopneumoniae strain. BMC Vet Res. 2012;8:24.

27. Thacker EL, Thacker BJ, Boettcher T, Jayappa H. Comparison of antibody production, lymphocyte stimulation, and protection induced by four commercial Mycoplasma hyopneumoniae bacteria. J Swine Health Prod. 1998;6:107–12.

28. Vicca J, Stakenborg T, Maes D, Butaye P, Peeters J, de Kruijff A, et al. Evaluation of virulence of Mycoplasma hyopneumoniae field isolates. Vet Microbiol. 2003;97:177–90.

29. Halbur PG, Paul PS, Meng XJ, Lum MA, Andrews JJ, Rathje JA. Comparative pathogenicity of nine US porcine reproductive and respiratory syndrome virus (PRRSV) isolates in a five-week-old cesarean-derived, colostrum-deprived pig model. J Vet Diagn Invest. 1996;8:11–20.

30. Hannan P, Bhogal B, Fish J. Tylosin tetratide and tiamulin effects on experimental piglet pneumonia induced with pneumonic pig lung homogenate containing mycoplasmas, bacteria and viruses. Res Vet Sci. 1982;33:76–8.

31. Morris CR, Gardner IA, Hietala SK, Carpenter TE. Enzootic pneumonia: comparison of cough and lung lesions as predictors of weight gain in swine. Can J Vet Res. 1995;59:197–204.

32. Kobirsch M, Tillon JP, Vannier P, Magueur S, Morvan P. Pneumonie enzootique á Mycoplasma suipneumoniae chez le porc: diagnostic rapide et recherché d’anticorps. Rec Med Vet Ec Alfort. 1978;154:847–52.

33. Marois C, Dory D, Fablet C, Madec F, Kobirsch M. Development of a quantitative Real-Time TaqMan PCR assay for determination of the minimal dose of Mycoplasma hyopneumoniae strain 116 required to induce pneumonia in SPF pigs. J Appl Microbiol. 2010;108:1523–33.